New combo therapy for bladder cancer shows promise but trial halted
NCT ID NCT04601857
First seen Jan 09, 2026 · Last updated May 15, 2026 · Updated 19 times
Summary
This study tested a combination of two drugs—futibatinib and pembrolizumab—in people with advanced or spreading bladder cancer who couldn't receive standard chemotherapy. The goal was to see if the combo could shrink tumors and be safe. The trial was stopped early after enrolling 43 participants, and results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED AND METASTATIC UROTHELIAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
ALTHAIA, Xarxa Assistencial Universitària de Manresa
Manresa, Brcelona, 8243, Spain
-
Centre Georges-François Leclerc
Dijon, Côte d'Or, 21079, France
-
Centre Leon Berard - departement d'oncologie medicale
Lyon, Rhone, 69373, France
-
Centre Regional de Lutte Contre le Cancer de Lorraine
Vandœuvre-lès-Nancy, 54500, France
-
Comprehensive Care Centers of Nevada
Las Vegas, Nevada, 89148, United States
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Henry Ford Hospital
Detroit, Michigan, 48202, United States
-
Hospital Clinic de Barcelona
Barcelona, 08036, Spain
-
Hospital Universitario HMN Sanchinarro
Madrid, 28050, Spain
-
Hospital Universitario Marqués de Valdecilla
Santander, 39008, Spain
-
Hospital Universitario Reina Sofia
Córdoba, 14004, Spain
-
Hospital Universitario Vall d'Hebrón
Barcelona, 8035, Spain
-
Hospital de La Santa Creu i Sant Pau
Barcelona, 8025, Spain
-
Hospital la Fe
Valencia, 46026, Spain
-
ICANS - Institut de cancérologie de Strasbourg Europe
Strasbourg, Bas-Rhin, 67200, France
-
Institut De Cancerologie Gustave Roussy
Villejuif, 94805, France
-
Institut Paoli Calmettes - Hôpital de jour
Marseille, Bouches-du-Rhône, 13273, France
-
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, California, 94158, United States
Conditions
Explore the condition pages connected to this study.